Combining cryoablation with immunotherapy for lung cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial compares the one-year survival benefit of combining cryoablation with pembrolizumab and pemetrexed-carboplatin against the standard treatment of pembrolizumab and pemetrexed-carboplatin alone in patients with metastatic lung adenocarcinoma. Participants will be randomly assigned to one of two arms: the experimental arm receiving cryoablation alongside the standard treatment, or the control arm receiving only the standard treatment. The study will assess tumor response using RECIST v1.1 criteria and will monitor participants for disease progression and treatment toxicity. The trial aims to determine if the addition of cryoablation improves survival outcomes for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically or cytologically confirmed non-small lung adenocarcinoma.
2. Metastatic disease.
3. Treatment with pembrolizumab in combination with pemetrexed-carboplatin as per market authorization.
4. At least two target lesions (RECIST1.1), measurable with CT or MRI :

   1. One target lesion that is amenable for accurate repeated measurements,
   2. One target lesion (15-40 mm) that is amenable for cryoablation treatment including lung, kidney, adrenal, soft tissue and lytic bone lesions. Liver and sclerotic bone lesions are not allowed to be treated by cryoablation.
5. Age ≥ 18.
6. Performance status ≤ 2.
7. Women of childbearing potential must have a negative serum pregnancy test prior to registration.
8. Recovery to grade ≤ 1 from any adverse event derived from previous treatment (excluding alopecia)
9. Patients with a social security in compliance with the French law (Loi Jardé).
10. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
11. Voluntarily signed and dated written informed consents prior to any study specific procedure.

Exclusion Criteria:

1. Squamous cell tumors and other than adenocarcinoma.
2. Prior systemic treatment for advanced non-small cell lung cancer (except adjuvant therapy after complete resection).
3. Current or prior use of immunosuppressive medication including any use of oral glucocorticoids, within 21 days before the first dose of pembrolizumab.
4. Known contra-indication and/or hypersensitivity to PD1/PD-L1 antagonist and/or cytotoxic therapy.
5. Known contra-indication to cryoablation.
6. Abnormal coagulation contraindicating biopsy.
7. Prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma or incidentally discovered good prognosis prostate cancer (T stage \< pT3 and Gleason ≤ 7).
8. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
9. Subjects who participated in an investigational drug or device study within 28 days prior to study entry.
10. Known infection with HIV, hepatitis B, or hepatitis C.
11. Females who are pregnant or breast-feeding.
12. Men or women refusing contraception.
13. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
14. Previous enrolment in the present study.
15. Individuals deprived of liberty or placed under legal guardianship.

Where it's running

• Institut Bergonié
  Bordeaux, Gironde, France Recruiting

Study contacts

• Principal investigator: Jean PALUSSIERE, MD — Institut Bergonié
• Study coordinator: Jean PALUSSIERE, MD
• Email: j.palussiere@bordeaux.unicancer.fr
• Phone: 05.56.33.33.47

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining Pembrolizumab, Bevacizumab, and Chemotherapy for Advanced Lung Cancer with ALK Mutation

  This study is testing a new combination of two drugs and chemotherapy to see if it helps people with advanced lung cancer that has an ALK mutation and hasn't improved with another treatment.

  Recruiting Phase 2 Hunan Province Tumor Hospital · Changsha, Hunan · NCT05266846

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer

  This study follows adults with muscle-invasive urothelial cancer to see how nerve-related side effects develop when people receive enfortumab vedotin and pembrolizumab around surgery as part of standard care.

  Recruiting at 3 sites Comprehensive Cancer Center Munich (CCCM) · Munich, Bavaria and 2 other locations · NCT07870577

• Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer

  This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07850791

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.